enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.85+0.13 (+7.56%)
Close on Nov 18, 2026Market cap $123.98MP/E –Yield 0.00%
enGene Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
enGene Therapeutics's operating income for the twelve months ending Jul 31, 2026 was -$136.65M. For fiscal 2025 it was -$123.17M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -$123.17M | – |
| FY2024 | Oct 31, 2024 | -$62.30M | – |
| FY2023 | Oct 31, 2023 | -$26.06M | – |
| FY2022 | Oct 31, 2022 | -$19.43M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -$34.01M | – |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -$31.97M | – |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -$31.19M | – |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -$39.48M | – |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -$29.95M | – |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -$27.12M | – |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -$26.61M | – |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | -$17.46M | – |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -$16.76M | – |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -$17.31M | – |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -$10.77M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -$10.44M | – |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -$6.25M | – |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | -$4.74M | – |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | -$4.63M | – |
See a number that looks wrong?